Genmab AS (GMAB)vsVertex Pharmaceuticals Inc (VRTX)
GMAB
Genmab AS
$32.47
+0.74%
HEALTHCARE · Cap: $20.65B
VRTX
Vertex Pharmaceuticals Inc
$519.51
+0.79%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 205% more annual revenue ($12.59B vs $4.13B). VRTX leads profitability with a 35.0% profit margin vs 19.1%. VRTX appears more attractively valued with a PEG of 1.89. VRTX earns a higher WallStSmart Score of 64/100 (C+).
GMAB
Buy53
out of 100
Grade: C-
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+48.6%
Fair Value
$58.54
Current Price
$32.47
$26.07 discount
Margin of Safety
+46.5%
Fair Value
$963.47
Current Price
$519.51
$443.96 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.2%
Revenue surging 24.9% year-over-year
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Weak financial health signals
Expensive relative to growth rate
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GMAB
The strongest argument for GMAB centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 19.1% and operating margin at 35.2%. Revenue growth of 24.9% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : GMAB
The primary concerns for GMAB are P/E Ratio, Altman Z-Score, Piotroski F-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
GMAB profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
GMAB carries more volatility with a beta of 0.70 — expect wider price swings.
GMAB is growing revenue faster at 24.9% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 53/100), backed by strong 35.0% margins and 12.5% revenue growth. GMAB offers better value entry with a 48.6% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Genmab AS
HEALTHCARE · BIOTECHNOLOGY · USA
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?